Teva Pharma (TEVA) Tops Q4 EPS by 17c, FY18 Guidance Falls Short of Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Teva Pharma (TEVA) PT Lowered to $23 at Goldman Sachs; Remains Bullish as Expectations Reset
February 9, 2018 8:52 AM ESTGoldman Sachs lowered its price target on Teva Pharma (NYSE: TEVA) to $23.00 (from $25.00) while maintaining a Buy rating following the company's 4Q earnings and meetings with management.
While 2018 guidance came in lower than expected, analyst Jami Rubin believes it helps reset investor expectations and,... More
Teva Pharma (TEVA) PT Lowered to $16.50 at Wells Fargo
February 9, 2018 8:05 AM ESTWells Fargo lowered its price target on Teva Pharma (NYSE: TEVA) to $16.50 (from $17.00) while maintaining an Underperform rating.
"We believe the conference call went poorly and reinforced worries about the weak 2018 guidance," analyst David Maris commented.
Lowers FY 2018 EPS to $2.43, which compares to Tevas guidance of $2.25-2.50.
... MoreTeva Pharma (TEVA) PT Lowered to $16 at Cowen
February 8, 2018 12:37 PM ESTCowen lowered its price target on Teva Pharma (NYSE: TEVA) to $16.00 (from $18.00) while maintaining a Market Perform rating.
Analyst Ken Cacciatore commented, "We have updated our model. The bottom-line is with the free cash flow expected to reach $2.6-2.8B this doesn't... More
Teva Pharma (TEVA) Leaving Room for Upside Surprise in EBITDA Guidance - Evercore ISI
February 8, 2018 8:32 AM ESTEvercore ISI analyt Umer Raffat said Teva Pharma (NYSE: TEVA) EBITDA expectations at $4.7-$5B (vs sell side at $5.3B) leaves a "healthy room in there for surprising to the upside either on more realized cost cuts or on lesser Copaxone erosion."
"Said another... More
